Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Operating Margin (2019 - 2025)

Historic Operating Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1513.47%.

  • Avidity Biosciences' Operating Margin rose 26874700.0% to 1513.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 2934.9%, marking a year-over-year increase of 2744500.0%. This contributed to the annual value of 3477.43% for FY2024, which is 10130200.0% down from last year.
  • As of Q3 2025, Avidity Biosciences' Operating Margin stood at 1513.47%, which was up 26874700.0% from 4448.71% recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Operating Margin ranged from a high of 882.29% in Q1 2021 and a low of 8360.9% during Q1 2025
  • For the 5-year period, Avidity Biosciences' Operating Margin averaged around 2731.32%, with its median value being 2125.76% (2022).
  • Examining YoY changes over the last 5 years, Avidity Biosciences' Operating Margin showed a top increase of 26874700bps in 2025 and a maximum decrease of -61823300bps in 2025.
  • Quarter analysis of 5 years shows Avidity Biosciences' Operating Margin stood at 2081.37% in 2021, then grew by 8bps to 1922.17% in 2022, then crashed by -58bps to 3043.46% in 2023, then tumbled by -34bps to 4069.63% in 2024, then soared by 63bps to 1513.47% in 2025.
  • Its Operating Margin was 1513.47% in Q3 2025, compared to 4448.71% in Q2 2025 and 8360.9% in Q1 2025.